Canopy Growth Narrows Losses but Stock Lags on Investor Skepticism
Despite operational improvements and reduced quarterly losses, Canopy Growth shares remain flat as investors question path to profitability.
Tablet, magnifying glass, and clipboard for stock market analysis.
Operational Metrics Show Progress
Canopy Growth narrowed its net loss to $47 million in Q2 2026, down from $89 million in the prior-year quarter, according to the company's September 12 earnings release. Revenue declined 8% year-over-year to $71 million, but gross margin expanded 420 basis points to 31%, driven by cost reductions in cultivation and distribution. SG&A expenses fell by $22 million compared to the same quarter last year.
CEO David Klein attributed the margin expansion to facility consolidations completed in late 2025 and early 2026, which eliminated redundant overhead in Ontario and British Columbia. Canopy now operates three cultivation facilities in Canada. Down from seven in 2024.
Stock Performance Disconnected from Fundamentals
Canopy Growth shares closed at $1.87 on September 13, down 41% year-to-date and near the stock's 52-week low of $1.62. The disconnect between improving operations and stagnant share price reflects broader investor fatigue with Canadian licensed producers, which have collectively destroyed $30 billion in market capitalization since 2019 peaks.
Daily volume on the Nasdaq has averaged 4.2 million shares over the past month, well below the 7.8 million average in 2025. Institutional ownership dropped to 18% in Q2 2026 from 31% a year earlier, according to FactSet data.
Path to Profitability Remains Unclear
Analysts project Canopy won't achieve positive adjusted EBITDA until Q4 2027 at the earliest, contingent on U.S. market entry or international expansion. The company burned $38 million in operating cash flow in Q2 and holds $112 million in cash against $310 million in convertible debt maturing in June 2027.
Klein declined to provide specific guidance on the earnings call but said the company's "evaluating strategic partnerships" for U.S. distribution. That language echoes statements made in prior quarters without concrete follow-through. The U.S. remains federally illegal for THC products, limiting Canopy's options to CBD or hemp-derived cannabinoids.
Investor Sentiment Anchored by Dilution Risk
Canopy has issued 1.2 billion shares since 2018, diluting early shareholders by 87% on a per-share basis. The company's market capitalization sits at $740 million, less than half the $1.6 billion Constellation Brands invested between 2017 and 2019. Constellation wrote down its stake by $2.3 billion in 2023 and hasn't participated in subsequent capital raises.
The overhang of potential equity raises weighs on the stock, and analysts at Stifel and Canaccord both model additional dilution in 2027 to refinance the convertible notes. Without a clear catalyst — U.S. federal legalization, a major acquisition, or a breakout brand — retail and institutional buyers have stayed on the sidelines.
For full background on this story, see the CannIntel topic hub on Canopy Growth stock performance.
What Investors Are Watching
The next inflection point is the June 2027 debt maturity and whether Canopy can secure refinancing without issuing equity at current depressed valuations. A U.S. rescheduling decision by the DEA, expected in late 2026 or early 2027, could unlock pathways for Canadian LPs to enter American markets through partnerships or acquisitions. Until then, operational improvements alone haven't been enough to move the stock.
Klein's track record includes the BioSteel write-down and multiple restructurings. Credibility is thin. The market's waiting for proof, not promises.
Frequently asked questions
Why is Canopy Growth stock down despite narrowing losses?
Investors remain skeptical of the timeline to sustained profitability and fear additional dilution from the June 2027 debt maturity. Operational improvements haven't translated to a clear path to positive cash flow, and the stock reflects fatigue with Canadian licensed producers that have destroyed $30 billion in market cap since 2019.
When will Canopy Growth be profitable?
Analysts project positive adjusted EBITDA no earlier than Q4 2027, contingent on U.S. market entry or major international expansion. The company must also refinance $310 million in convertible debt maturing in June 2027, likely requiring additional equity dilution at current valuations.
What is Canopy Growth's cash position?
Canopy held $112 million in cash at the end of Q2 2026 and burned $38 million in operating cash flow during the quarter. With $310 million in debt maturing in nine months, the company will need to refinance or raise capital before mid-2027.
Can Canopy Growth enter the U.S. THC market?
Not yet. Federal prohibition prevents Canadian licensed producers from directly selling THC products in the U.S. Canopy is limited to CBD and hemp-derived cannabinoids until federal rescheduling or legalization occurs. The DEA is expected to issue a rescheduling decision in late 2026 or early 2027.
How much has Canopy Growth diluted shareholders?
Canopy has issued 1.2 billion shares since 2018, diluting early shareholders by 87% on a per-share basis. The company's market cap is $740 million, less than half the $1.6 billion Constellation Brands invested, which wrote down its stake by $2.3 billion in 2023.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Business
Organigram enters fight for Aurora as Curaleaf bid clock runs
British American Tobacco's stake in Organigram could put the tobacco giant at the center of the Aurora contest before Curaleaf's offer expires Dec. 4.
Tilray Medical Wins Approval for In-House EU-GMP Cannabis Testing
Tilray Medical can now run EU-GMP quality testing in-house, a move that could shift lab costs and batch-release timing, though key details remain undisclosed.
Canopy Growth Secures EU-GMP Certification at Smiths Falls
Canopy Growth's Smiths Falls site is now certified for softgel manufacturing and primary packaging of softgels, oral liquids and dried flower, extending its EU-GMP supply chain.
More from the newsroom
Puerto Rico Rolls Back Medical Cannabis Workplace Protections
High Times Magazine reports Puerto Rico has narrowed employment protections for medical cannabis patients, raising questions about which workers lose coverage and which keep it.
L.A. Cannabis Industry Rallies Behind Nithya Raman, Substack Reports
A High Adam post says Los Angeles operators are energizing around Councilmember Nithya Raman, but the platform details behind the 'actual plan' remain unverified.
County Commissioners Vote for Cannabis Moratorium, Herald Reports
A county board voted to pause new cannabis operations, the Austin Daily Herald reported, adding to Minnesota's patchwork of local rules under the 2023 adult-use law.